vanadates has been researched along with Lymphoma, Non-Hodgkin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ma, YP; McKnight, HC; O'Donnell, RT; Pearson, D; Tuscano, JM | 2 |
2 other study(ies) available for vanadates and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
Phosphatase inhibition augments anti-CD22-mediated signaling and cytotoxicity in non-hodgkin's lymphoma cells.
Topics: Antibodies, Monoclonal; Apoptosis; Cell Line, Tumor; Enzyme Activation; Flow Cytometry; Genes, Dominant; Humans; Hydroquinones; Immunoblotting; Immunoglobulin M; Lymphoma, Non-Hodgkin; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinase 8; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Signal Transduction; Vanadates | 2009 |
Treatment of non-Hodgkin's lymphoma xenografts with the HB22.7 anti-CD22 monoclonal antibody and phosphatase inhibitors improves efficacy.
Topics: Animals; Antibodies, Monoclonal; Apoptosis; Flow Cytometry; Humans; Immunotherapy; Lymphoma, Non-Hodgkin; Mice; Mice, Inbred BALB C; Mice, Nude; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Sialic Acid Binding Ig-like Lectin 2; Tumor Cells, Cultured; Vanadates; Xenograft Model Antitumor Assays | 2009 |